The abstract is read at the publisher; the summary is JClub's.
Targeting DKK1 in second-line metastatic colorectal cancer did not significantly change treatment outcomes in the phase II DeFianCe trial.
- Why it matters: Second-line options for metastatic colorectal cancer remain limited, and there is a need for biomarker-driven strategies that improve outcomes.
- What they did: The phase II DeFianCe trial evaluated DKK1 targeting in patients with metastatic colorectal cancer receiving second-line treatment.
- The result: The lack of significant outcome change suggests DKK1 may not be an effective second-line treatment target in this setting, informing future biomarker efforts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.